A vaccine scandal in China, which has hit a nerve in the country and prompted quick reactions from leaders in Beijing, is sending ripples across the wider domestic drug market while threatening to dent Chinese ambitions to play a larger global role.
Shares in Chinese vaccine makers and biotech firms fell across the board Monday after Premier Li Keqiang slammed Changsheng Biotechnology Co. for having crossed a moral red line and called for swift action.
The case erupted a week ago when Changsheng was found to have violated standards in making rabies vaccine.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.